{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-144226","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.299222+00:00","generated_at":"2026-06-15T01:06:10.826836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CalciMedica Q1 net loss $19.3M ($23.43/sh); cash $34.2M; Nasdaq delisted","bullets":["Net loss $19.3M ($23.43 diluted EPS); operating expenses $22.3M incl. $16.2M one-time Graybug merger costs.","Cash, equivalents and short-term investments $34.2M as of March 31; expects runway into H2 2024.","CARPO Phase 2b trial: IDMC reviewed first 90 pts, recommended continue; expects topline Q1 2024.","Stock suspended from Nasdaq March 30; now trading on OTCQB, working to relist.","Merger with Graybug closed March 20; CalciMedica equityholders own ~72%, Graybug ~28%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-144226","json":"https://secwatch.observer/filing/0001193125-23-144226.json","markdown":"https://secwatch.observer/filing/0001193125-23-144226.md","text":"https://secwatch.observer/filing/0001193125-23-144226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/0001193125-23-144226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/d463877d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:06:10.826836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"519976273b1fc26488b6ca874b5378c2eb5a8639","claim":"CalciMedica, Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023., EPS $23.43 per share (basic and diluted).","evidence_excerpt":"Financial Results for the Three Months Ended March 31, 2023: • Cash, Cash Equivalents and Marketable Securities: As of March 31, 2023, CalciMedica had $34.2 million in cash, cash equivalents and short-term investments. • Total Operating Expenses: Total operating expenses were $22.3 million, which included $16.2 million of one-time charges related to accelerated vesting and severance for employees of Graybug Vision, Inc. (Graybug) at the time of the merger with Graybug. • Net Loss: Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/0001193125-23-144226-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023."},{"label":"EPS","value":"$23.43 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}